Frontlight ResearchEarly access
Taking people in NetherlandsPhase 4
Testing one blood level check to adjust blood thinners in frail older adults
Tests one blood thinner level check and dose change in frail older adults.
Key facts
- Who runs it
- Academisch Ziekenhuis Maastricht
- Where
- Maastricht, NetherlandsSee the 2 sites
- Trial code
- Registry title
- Assessing the Efficacy of a Single Measurement and Adjustment Strategy for DOACs in Frail Older Patients.
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 2,000 people, planned
- Started
- 6 Jan 2026
- Expected to end
- 1 Sept 2030
- Type of study
- Interventional
- Record updated
- 22 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for frail older adults who take a blood thinner (a DOAC) and can give informed consent. It tests a one-time blood level check and dose adjustment.
- Age
- Older than 70 years
- Sex
- All sexes can join
- Disease stage
- Frail, with a Clinical Frailty Scale (CFS) score above 3
- Earlier treatment
- Must be using a DOAC; people who are just starting a DOAC are preferred
Main reasons for not taking part
- Life expectancy under 3 months
- Not able to give informed consent
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- In order to be eligible to participate in this study, a subject must meet all of the following criteria: (a) aged > 70 years; (b) using a DOAC (preferably among new users, defined as participants initiating treatment with a DOAC), (c) CFS > 3, (d) able to attend to the outpatient clinic (only applicable to community dwelling patients), and (e) able to provide informed consent
Who cannot take part
- A potential subject who meets any of the following criteria will be excluded from participation in this study: (1) a life expectancy < 3 months, (2) not able to provide informed consent
Where in Netherlands
- EnvidaMaastricht, NetherlandsTaking people
- MUMC+Maastricht, NetherlandsTaking people
About the trial
What the trial wants to find out
The primary aim of this study is to evaluate the efficacy of a Single Measurement and adjustment strategy based on DOAC levels in the frail older population on the incidence of complications, in particular thromboembolic events or bleedings as composite outcome.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Assessing the Efficacy of a Single Measurement and Adjustment Strategy for DOACs in Frail Older Patients: Insights from the DOAC-FRAIL RCT. A step towards safe(r) DOAC utilization in the frail older population.
- Plain-language title
- Testing one blood level check to adjust blood thinners in frail older adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 22 December 2025